Publications by authors named "Anna Melone"

Claim this Profile
B
Basophil activation test: How many basophils are enough?
Léonard Bezinge, Dominik Vogt, Anna Melone, Maximilien Lartigue, Cédric Giegelmann

Allergy· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Emilia Salvadori, Anna Poggesi, Ida Donnini, Valentina Rinnoci, Guido Chiti, Anna Melone

Drugs Aging· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein.
Larissa Brosi, Eric Kübler, Anna Weston, Patrick Romann, Sherin Panikulam, Anna Melone

Chimia (Aarau)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(Difluoromethyl)-5-(4-((3,5)-3,5-dimethylmorpholino)-6-(()-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.
Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Anna Melone

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Motor and Cognitive Performances in Elderly With Atrial Fibrillation: Strat-AF Study.
Emilia Salvadori, Francesco Galmozzi, Francesca Uda, Carmen Barbato, Eleonora Camilleri, Anna Melone

Front Neurol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
Emilia Salvadori, Anna Poggesi, Ida Donnini, Valentina Rinnoci, Guido Chiti, Anna Melone

Aging Clin Exp Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Chiara Borsari, Denise Rageot, Florent Beaufils, Thomas Bohnacker, Erhan Keles, Anna Melone

ACS Med Chem Lett· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
Chiara Borsari, Denise Rageot, Alix Dall'Asen, Thomas Bohnacker, Anna Melone

J Med Chem· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Biological Markers for Cerebral Bleeding Risk STRATification in Patients with Atrial Fibrillation on Oral Anticoagulants for Primary or Secondary Prevention of Ischemic Stroke (Strat-AF Study): Study Design and Methodology.
Anna Poggesi, Carmen Barbato, Francesco Galmozzi, Eleonora Camilleri, Francesca Cesari, Anna Melone

Medicina (Kaunas)· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
()-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A McPhail, Reece M Hoffmann, Anna Melone

J Med Chem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari

J Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Claudia Brandt, Petra Hillmann, Andreas Noack, Kerstin Römermann, Leon A Öhler, Anna Melone

Neuropharmacology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone

J Med Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Thomas Bohnacker, Andrea E Prota, Florent Beaufils, John E Burke, Anna Melone

Nat Commun· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Separation and detection of all phosphoinositide isomers by ESI-MS.
Sabine Kiefer, Johannes Rogger, Anna Melone, Ann C Mertz, Anna Koryakina

J Pharm Biomed Anal· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis